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ABSTRACT
Background: Chronic myeloid leukemia (CML) results from hematopoietic stem 
cell transformation by the bcr-abl chimeric oncogene, encoding a 210 kDa protein 
with constitutive tyrosine kinase activity. In spite of the efficiency of tyrosine kinase 
inhibitors (TKI; Imatinib), other strategies are explored to eliminate CML leukemia 
stem cells, such as calcium pathways. 
Results: In this work, we showed that Store-Operated Calcium Entry (SOCE) 
and thrombin induced calcium influx were decreased in Bcr-Abl expressing 32d cells 
(32d-p210). The 32d-p210 cells showed modified Orai1/STIM1 ratio and reduced 
TRPC1 expression that could explain SOCE reduction. Decrease in SOCE and thrombin 
induced calcium entry was associated to reduced Nuclear Factor of Activated T cells 
(NFAT) nucleus translocation in 32d-p210 cells. We demonstrated that SOCE blockers 
enhanced cell mobility of 32d-p210 cells and reduced the proliferation rate in both 
32d cell lines. TKI treatment slightly reduced the thrombin-induced response, but 
imatinib restored SOCE to the wild type level. Bcr-Abl is also known to deregulate 
Protein Kinase C (PKC), which was described to modulate calcium entries. We showed 
that PKC enhances SOCE and thrombin induced calcium entries in control cells while 
this effect is lost in Bcr-Abl-expressing cells.
Conclusion: The tyrosine kinase activity seems to regulate calcium entries 
probably not directly but through a global cellular reorganization involving a PKC 
pathway. Altogether, calcium entries are deregulated in Bcr-Abl-expressing cells and 
could represent an interesting therapeutic target in combination with TKI.
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INTRODUCTION
Chronic myeloid leukemia (CML) results from 
hematopoietic stem cell transformation by the bcr-abl 
chimeric oncogene, generated by a reciprocal translocation 
between chromosomes 9 and 22 (Philadelphia chromosome, 
Ph+) [1]. CML is a myeloproliferative disorder that 
progresses from initial chronic phase to accelerated phase 
and terminal blast crisis. The structure of the generated 
protein (p210bcr-abl) consists of functional domains which 
are successively oligomerization, serine/threonine kinase, 
RhoA-specific DH/PH (Dbl-Homology/Pleckstrin 
homology), SH2 and SH3, tyrosine kinase and actin 
binding domains [2]. In parallel to the tyrosine kinase 
domain, responsible for leukemogenesis, all these domains 
participate to the general deregulation of the intracellular 
signaling pathways in Bcr-Abl-expressing cells. Bcr-Abl 
tyrosine kinase inhibitors (TKI) are remarkably effective 
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in inducing remissions, preventing transformation to 
blast crisis, and prolonging survival of CML patients [3]. 
However, TKI treatment fails to eliminate leukemic stem 
cells (LSC), even in patients achieving deep molecular 
responses [4]. Although a subset of CML chronic phase 
patients are able to maintain remission after stopping TKI, 
most patients require continuous treatment to prevent 
relapse [5]. Therefore, improved understanding of the 
mechanisms of LSC resistance to TKI should help to 
develop new strategies to obtain treatment-free remissions.
In CML, the constitutively activated tyrosine-kinase 
activity of Bcr-Abl generates in stem cells, but also in 
differentiated cells, multiple signaling abnormalities, 
leading to enhanced proliferation, inhibited apoptosis and 
stimulated migration. It prompted numerous research teams 
to explore other signaling pathways that could provide 
alternate therapeutic targets, especially for treating cancer 
progenitors. Calcium (Ca2+) signaling pathways could be 
an alternate therapeutic target because of its importance 
in various cellular processes such as proliferation, protein 
expression and migration in normal and cancer cells. 
In particular, Ca2+ channels expressed at the plasma 
membrane (PM) could offer potential therapeutic targets 
and/or prognostic markers. Ca2+ channels are indeed major 
actors that transduce microenvironment signals into spatio-
temporal fluctuations of intracellular Ca2+ concentrations 
and in turn modulate specific cellular mechanisms. The 
amplitude of the cytoplasmic Ca2+ variation regulates the 
responses such as local or global Ca2+ increase coming from 
extracellular entries and/or intracellular stock release [6]. 
Cancer cells hijack the physiological functions of those 
channels, which then contribute to the neoplastic phenotype. 
In non-excitable cells, the main Ca2+ entry is mediated 
through the binding of an agonist (thrombin, catecholamine, 
bradykinin, etc.) on its tyrosine kinase receptor or G protein 
coupled receptor (GPCR) which activates phospholipase C 
(PLC). PLC mediates the cleavage of phosphatidylinositol 
4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (IP3). DAG stimulates receptor-
operated channels (ROCs) via protein kinase C (PKC) 
activation. ROCs are mainly members of transient receptor 
potential canonical (TRPC) family (for example TRPC1-3-6) 
and contribute to the cytosolic Ca2+ increase [7]. In parallel 
to PKC activation, the formation of IP3 triggers Ca
2+ release 
from the endoplasmic reticulum (ER) which stimulates 
store-operated channels (SOCs) (for review: [8, 9]). Stromal 
interaction molecule 1 (STIM1) is an ER Ca2+ sensor that 
oligomerizes when ER Ca2+ concentration diminishes, 
moves to the ER/PM junctions and then binds to the PM 
Orai1 channels [10–12]. STIM1 and Orai1 are the main 
components of store-operated Ca2+ entry (SOCE), also called 
Ca2+ release-activated Ca2+ (CRAC) channels. The molecular 
interaction of STIM1/Orai is now well documented [13–16]. 
Moreover, different members of TRPC family have also been 
involved in SOCE (for review: [17]). For example, TRPC1 
can interact with STIM1 [18, 19] and in turn contribute to 
SOCE in different tissues (salivary gland, smooth muscle, 
endothelial, etc.) (for review: [7, 20]). In salivary gland 
cells, STIM1/Orai1 dependent Ca2+ entry contributes to 
the targeting of TRPC1 from vesicles to PM in the ER/PM 
junctions. TRPC1 translocation allows the co-localization 
with STIM1 and Orai1 and then TRPC1 participates to 
SOCE amplification [21, 22]. 
Because Ca2+ is involved in numerous cellular 
processes, Ca2+ regulation has also been studied in various 
pathologies and especially in cancer. Ca2+ channels and 
pumps are known to be deregulated in various tumors 
and could be used as cancer hallmarks (for review: 
[23–25]). STIM, Orai and TRP channels and in turn Ca2+ 
homeostasis play a role in cell processes that are modified 
in tumor context [26–30] but their expression levels and 
activation are dependent of cancers types and will have 
different functional consequences. 
In CML, very few studies investigate the link 
between Ca2+ homeostasis and leukemogenesis. In fact, 
the two publications exploring the relationships between 
Bcr-Abl expression and Ca2+ are now relatively old and 
propose opposite results [31, 32]. In Bcr-Abl-expressing 
cells, Piwocka et al., showed that the Bcr-Abl-expressing 
cells have a decrease in ER Ca2+ release as well as a 
reduced SOCE, which inhibit Ca2+-dependent apoptosis 
[31]. In another study, the tyrosine kinase activity of Bcr-
Abl enhances SOCE via PKC inhibition, that positively 
regulates survival factors [32]. These works were done 
concurrently with the discovery of the molecular actors 
of SOCE: Orai/STIM. Therefore, few data are available 
for Ca2+/SOCE/CML and the current treatment of CML 
inhibits tyrosine kinase activity of Bcr-Abl but cannot give 
a free remission of the disease. We investigated the role of 
the Ca2+ signaling in Bcr-Abl-expressing cells in order to 
find new pharmacological targets in LSC.
In this study, we described the different Ca2+ influxes 
in 32d-p210 cells compared to wild type (WT) cells: Ca2+ 
entries in response to thrombin or to pharmacological store 
depletion are reduced in Bcr-Abl-expressing cells. The 
decrease of SOCE is not related to Orai1/STIM1 proteins 
expression but most probably to a change of stoichiometry. 
In Bcr-Abl-expressing cells, the decrease of SOCE is 
also accompanied by a reduction of the Nuclear Factor 
of Activated T cells (NFAT) translocation and regulates 
cell proliferation and migration. Tyrosine kinase activity 
of Bcr-Abl does not regulate directly Ca2+ homeostasis but 
participates to the general disorganization of cell function 
in leukemia cells notably via Protein Kinase C (PKC).
RESULTS
Calcium influxes in Bcr-Abl-expressing cells
In order to study the Bcr-Abl-dependent Ca2+ 
homeostasis, we characterized the different Ca2+ influxes in 
32d cells wild type (32dWT) or stably transfected with the 
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p210bcr-abl oncogene (32d-p210). For all the Ca2+ experiments, 
32d cells (WT and -p210) were immobilized on fibronectin-
coated coverslips and the ratiometric Ca2+ indicator dye Fura-
2-Acetoxymethyl ester (Fura-2 AM) was used to analyze 
Ca2+ variation of single cells. We first studied the basal Ca2+ 
“leak”. To measure a constitutive Ca2+ influx, cells were 
incubated very briefly (30 or 40 seconds) in an extracellular 0 
mM Ca2+ solution and quickly changed to 1.8 mM Ca2+ buffer 
(Figure 1A). With this protocol, a weak decrease of the ratio 
of fluorescence during the incubation of 0 mM Ca2+ buffer 
was observed, showing the basal Ca2+ entry in resting cells. 
Then, the 1.8 mM Ca2+ buffer incubation allowed the return 
to the basal level, suggesting that no other Ca2+ channels were 
activated after this phase (Figure 1A). To increase the gradient 
toward the membrane, the same experiments were performed 
with a 5 mM Ca2+ instead of 1.8 mM Ca2+. In our cells lines, 
the constitutive Ca2+ influx was weak in presence of 1.8 or 
5 mM Ca2+ buffer and may not play a predominant role in Ca2+ 
homeostasis. Moreover, no difference was measured between 
WT and Bcr-Abl-expressing cells (Figure 1B) suggesting that 
no constitutive Ca2+ entry is increased contrary to what has 
been observed in other types of cancer cells [33].
To investigate the GPCR activated pathways, cells 
were treated with 1 U/ml of thrombin. The thrombin-evoked 
intracellular Ca2+ responses were characterized by a quick 
peak with a rapid rising phase, followed by a longer sustained 
phase during which the intracellular Ca2+ remained relatively 
high and slowly decreased (Figure 1C). The rapid phase of 
the Ca2+ increase was analyzed by the maximum of the peak 
(maximum of response) while the half-time of response was 
used for evaluating the duration of the sustained phase (Figure 
1D). The maximum peak decreased slightly in 32d-p210 cells 
compared to 32dWT and the sustained phase showed a strong 
reduction in 32-p210 cells (Figure 1C and 1D). In conclusion, 
Bcr-Abl expression induced a decrease of thrombin-
dependent Ca2+ response. This experiment measured a 
global cytosolic Ca2+ signal but could not distinguish 
between intracellular stock release and entry through PM. To 
understand the thrombin-dependent Ca2+ response, cytosolic 
Ca2+ variations were observed in presence of extracellular 
0 mM Ca2+ solution (Figure 2A). In these conditions, the peak 
of response increased in 32dWT showing that this first phase 
depends mainly on Ca2+ intracellular stock release and not on 
an extracellular entry (Figure 2B). Moreover, the small gain 
could be due to a reaction of the cells stressed by a lack of 
extracellular Ca2+. However, the incubation of 32d-p210 cells 
in 0 mM Ca2+ leaded to a small decrease of the maximum, 
which turned back to the 32dWT level in 1.8 mM Ca2+ buffer 
(Figure 2B). Besides, the half-time of response was strongly 
decreased in both cells lines in 0 mM Ca2+ buffer. This result 
shows that the second phase of the intracellular response 
mainly involves the extracellular Ca2+ entries (Figure 
2C). The reduction of the slow sustained phase was more 
pronounced in control cells compared to Bcr-Abl-expressing 
cells. This suggests that the longer sustained phase in 32dWT 
cells is due to higher level of Ca2+ entries. Because the main 
Ca2+ influx in non-excitable cells is SOCE, their implication 
in the sustained phase was investigated. We did not succeed 
in efficiently transfecting both cell lines so we used two 
pharmacological Ca2+ influxes inhibitors: YM-58483 and 
SKF-96365 (Figure 2D). In 32dWT, treatment with inhibitors 
resulted in a strong decrease of the half-time of thrombin-
dependent Ca2+ response (Figure 2D and 2F) reaching the 
value to that of the 32d-p210 cells in normal conditions. 
YM-58483 and SKF-96365 induced a slight reduction of the 
half-time of response in 32d-p210. This result shows that the 
difference in half-time of thrombin response between control 
and Bcr-Abl-expressing cells is due to Ca2+ entry through 
PM Ca2+ channels. This suggests that a reduction of SOCE 
in Bcr-Abl-expressing cells is responsible of the decreased 
sustained phase during the thrombin-elicited Ca2+ signal. 
The maximum of response did not show notable changes 
in WT cells during inhibitors incubation in contrast to the 
Bcr-Abl-expressing cells (Figure 2D and 2E). Same results 
were obtained using another SOC inhibitor: GSK-7975A 
(Supplementary Figure 1C). In these latter cells, YM-58483 
or SKF-96365 treatment induced a decrease of the maximum 
of response suggesting that the increase of the peak measured 
in 32d-p210 cells (Figure 1D) could be due to Ca2+ entry 
through PM. 
SOCE is reduced in Bcr-Abl-expressing cells
Because thrombin signaling induces several Ca2+ 
pathways, we investigated SOCE with specific protocols. 
Incubation with a sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA) inhibitor (cyclopiazonic acid (CPA)) 
induces the decrease of ER Ca2+ concentration and then 
the activation of SOCs (Orai1 and TRPC1) via STIM1 
dimerization [14, 20]. The ER Ca2+ release was analyzed 
by the maximum and the quantity (area under the curve) 
of cytoplasmic Ca2+ increase in CPA-0 mM Ca2+ conditions 
(Figure 3A and 3B). With this protocol, the ER depletion 
maximum and amplitude were lower in Bcr-Abl-expressing 
cells compared to control cells, as previously described 
and linked to a B-cell lymphoma 2 protein (Bcl-2) 
independent inhibition of apoptotic signaling [31]. After 
ER depletion induced SOCs activation, incubation with 
1.8 mM Ca2+ solution was followed by a Ca2+ entry 
through SOCs. This Ca2+ influx was characterized by the 
rate of entry (measured by the slope of the curve) and the 
maximum of cytosolic Ca2+ increase (maximum). Bcr-Abl-
expressing cells displayed a decrease in the rising slope 
and in the maximum of Ca2+ entry, compared to 32dWT 
cells (Figure 3C). Same results were obtained after the 
incubation with ER Ca2+ chelator (N,N,N’,N’-tetrakis(2-
pyridylmethyl)ethane-1,2-diamine (TPEN)) that mimicked 
the decrease of ER Ca2+ concentration (Figure 3C). 
SOCEs in 32d cells were also confirmed by the incubation 
of the inhibitor GSK-7975A (Supplementary Figure 1A, 
1B) These results show that Bcr-Abl expressing cells 
display reduced SOCE.
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To understand the origin of SOCE decrease in Bcr-
Abl-expressing cells, the expression of the major SOC 
components was studied and compared to control cells. 
We could not detect any difference in the Ribonucleic Acid 
(RNA) levels of STIM1 and Orai1 between 32dWT and 
32d-p210 cells (data not shown). Western Blot analyses 
revealed no difference of expression for the ER Ca2+ sensor 
STIM1 whereas an increase of Orai1 expression was shown 
in 32d-p210 cells (Figure 4A and 4B). Furthermore, TRPC1 
expression was decreased in these cells (Figure 4A and 4B). 
The decrease of TRPC1 expression is consistent with the 
reduced SOCE in 32d-p210 cells (Figure 3). Moreover, the 
STIM1 amounts seem not to be dependent on the Bcr-Abl 
expression in contrast to Orai1. The increase of the Orai1 
expression probably leads to a change of the stoichiometry 
between STIM1 and Orai1, that could also explain the 
reduced SOCE in 32d-p210 cells [34, 35].
Bcr-Abl is a constitutively active tyrosine 
kinase and regulation of STIM1, Orai1 and TRPC1 by 
phosphorylation has been well documented. For instance, 
PKC-induced phosphorylation of TRPC1 is known to 
enhance SOCE [36, 37], and Orai1 is also known to be 
inhibited by serine/threonine phosphorylation [38]. In 
order to study phosphorylation states of these proteins, 
Phos-Tag™ molecules were introduced into SDS-PAGE 
gel. This molecule binds the phosphate moiety of proteins 
and the in-gel complex formed is retained during sample 
electrophoresis. Each Phos-Tag™ molecule binds one 
phosphate and in consequence, each phosphorylation form 
of the protein can be isolated and visualized by Western 
Blot [39]. The use of Phos-Tag™ molecule modifies the 
Figure 1: Calcium entries in 32d cells. (A) Constitutive entries in 32dWT (dark) and 32d-p210 (grey) cells. Cells were plated on 
fibronectin-coated coverslips and loaded with Fura-2 AM. After incubation in 1.8 mM Ca2+ buffer, cells were perfused with 0 mM Ca2+ 
buffer for 30 seconds. Cytosolic Ca2+ variations were recorded by ratiometric fluorescence at 340/380 nm. (B) Quantification of constitutive 
Ca2+ entries in 32dWT and 32d-p210 cells. Cells were incubated in 1.8 or 5 mM Ca2+ solution and perfused with 0 mM Ca2+ buffer for 30 
or 40 seconds. The 340/380 nm ratio between the peak of decrease and the basal value has been measured. (C) Thrombin-induced Ca2+ 
entry in 32dWT (black line) and 32d-p210 (grey line) cells. Cells were plated on fibronectin-coated coverslips and incubated with 1 U/ml 
thrombin in 1.8 mM Ca2+ buffer. (D) Quantification of thrombin-induced Ca2+ entry in 32dWT (dark) and 32d-p210 (grey) by measured 
the peak of response (maximum in 340/380 nm fluorescence ratio) and the half time of response (in seconds). Bar graphs represent mean 
rates response ± SEM. ***P < 0.001.
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Figure 2: Characterization of thrombin-induced calcium entries. (A) Thrombin-induced Ca2+ entry in 32dWT cells in 
1.8 mM Ca2+ buffer (solid line) or 0 mM Ca2+ buffer (dotted line) in presence of 1 U/ml thrombin. Cells were plated on fibronectin-coated 
coverslips and loaded with Fura-2 AM. Cytosolic Ca2+ variations were recorded by ratiometric fluorescence at 340/380 nm. (B and C) 
Quantification of thrombin-induced Ca2+ entry in 1.8 mM Ca2+ buffer or 0 mM Ca2+ buffer in presence of 1 U/ml thrombin. The peak 
of response (maximum in 340/380 nm fluorescence ratio) and the half-time of response (in seconds) were measured in 32dWT (dark) 
and 32d-p210 (grey) cells. The control values are pooled from different experiments. (D) Thrombin-induced Ca2+ entry in 32dWT cells 
after treatment with Ca2+ channels blockers (YM-58483 and SKF-96365). Cells were pre-incubating or not (solid line) with 10 µM YM-
58483 (circle) or 40 µM SKF-96365 (triangle) during 5 minutes and incubated with 1 U/ml thrombin in 1.8 mM Ca2+ buffer. (E and F) 
Quantification of thrombin-induced Ca2+ entry with or without pre-incubation with 10 µM YM-58483 or 40 µM SKF-96365 during 
5 minutes and incubated with 1 U/ml thrombin in 1.8 mM Ca2+ buffer. Measurements are represented as the peak of response (maximum in 
340/380 nm fluorescence ratio) and the half-time of response (in seconds). Bar graphs represent mean rates ± SEM. ***P < 0.001.
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Figure 3: Store-Operated Calcium Entries (SOCE). (A) Store-operated Ca2+ entry in 32d cell lines in 32dWT (dark line) and 32d-
p210 (grey line). The ER depletion were trigged by 15 μM CPA (SERCA inhibitor) in 0 mM Ca2+ solution which allowed SOCE in presence 
of 1.8 mM Ca2 prior to a 0 mM Ca2+ buffer incubation. (B) Quantification of ER depletion with the maximum of depletion (340/380 nm 
fluorescence ratio) and the amount of Ca2+ release (area under the curve) after normalization of the response. (C) SOCE measurements in 
32dWT (dark) and 32d-p210 (grey) cells with the maximum (340/380 nm fluorescence ratio; left panel) and the speed of entries (initial 
slope; right panel). SOCE were induced by ER depletion with the 0 mM Ca2+-15 µM SERCA inhibitor CPA or with 0 mM Ca2+-1 mM ER 
Ca2+ chelator TPEN for 5 minutes. Bar graphs represent mean rates ± SEM. ***P < 0.001.
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sample migration into the gel and then apparent molecular 
weight is not reliable. These experiments allow a direct 
observation of phosphoproteins as well as their levels 
of phosphorylation. Therefore, 32dWT and 32d-p210 
lysates were treated or not with CPA in order to activate 
SOCs. The dephosphorylated form of the protein was 
used as a control (Figure 4C). In 32dWT and 32d-p210 
cells, TRPC1 presented a dephosphorylated form but 
no difference in normal or stimulated conditions could 
be observed. The tyrosine phosphorylation of STIM1 is 
required for Orai1 interaction in ER/PM junction (for 
review: [40, 41]). As expected, the CPA stimulation 
induced a STIM1 phosphorylation in both 32d cell lines, 
and we observed the presence of several phosphorylated 
forms of Orai1. Nevertheless, no statistical variations were 
measured in the ratio phosphorylated/non-phosphorylated 
Orai1 protein as well as in STIM1 and TRPC1 that 
could explain the reduced SOCE measured in Bcr-Abl-
expressing cells. These data suggest that no direct or 
indirect Bcr-Abl-dependent phosphorylation of main SOC 
components is involved in the observed SOCE decrease. 
The role of SOCE in 32d cells
In order to understand the functional consequences 
of SOCE decrease in Bcr-Abl-expressing cells, 
several Ca2+-regulated processes involved in leukemia 
development were studied. Nuclear factor of activated 
T cells (NFAT) is a Ca2+-dependent transcriptional 
factor that regulates various aspects of cellular function 
(including migration and proliferation). A cytoplasmic 
Ca2+ increase (via SOCs or ROCs) induces activation 
of the Ca2+-dependent phosphatase, calcineurin which 
dephosphorylates NFAT causing its translocation into the 
nucleus (for review: [42]). A long lasting Ca2+ response 
can maintain NFAT into the nucleus, which could be the 
support of differences in Ca2+-dependent transcription 
between 32dWT and 32d-p210 cells that display shorter 
Ca2+ responses to thrombin. The NFAT activation and 
translocation can be quantified by analyzing nucleus/
cytoplasm ratio of NFAT means intensity. Cells were 
treated with or without CPA incubation in presence of 
calcineurin inhibitor cyclosporine A (CsA) or SOCE 
inhibitors, fixed and labelled with anti-NFAT2 antibodies 
(Figure 5A). In control conditions 32dWT cells, 50% of 
NFAT2 signal was in the nucleus. In contrast in 32d-p210 
cells, NFAT2 signal was stronger in the cytoplasm (Figure 
5B). After SOCs activation by CPA, NFAT2 translocated 
into the nucleus in both cell lines although more protein 
translocated into the nucleus of 32dWT cells compared to 
32d-p210, a result consistent with the differences already 
observed in SOCE (CPA protocol) and ROCE (thrombin 
protocol) between the two cell lines (Figures 1 and 3). 
The use of SOCE inhibitors reduced NFAT2 translocation, 
confirming the link between SOCE and NFAT activation. 
Same results were obtained with NFAT1 (data not shown). 
Altogether, decreased Ca2+ influx in stimulated Bcr-Abl-
expressing cells led to a reduction of the activation of the 
NFAT Ca2+-dependent pathway. 
We next explored the impact of SOCE on 
proliferation of 32d cells. Bcr-Abl induces an increase of 
proliferation in leukemia cells mainly through its tyrosine 
kinase activity as already described [43] (Figure 5C). 
As expected, SOCE inhibition reduced also the rate of 
proliferation in 32d cells at 48 and 72 hours (Figure 5C). 
In fact, SOCE is known to regulate proliferation (for 
review: [27]) via several pathways (Extracellular signal-
Regulated Kinases (ERK), NFAT, etc.) and to modify 
transcription of genes involved in cell cycle. We showed 
that cell proliferation could also be reduced by treatments 
with Ca2+ channels blockers in 32d-p210 cells, suggesting 
that these inhibitors can counteract the positive effect of 
Bcr-Abl on cell cycle. These results (Figure 5C) suggest 
that Ca2+ entries could play a role in cells proliferation but 
the main regulator remains the constitutive tyrosine kinase 
activity of Bcr-Abl.
Since Bcr-Abl expression has also been involved 
in activation of amoeboid cell migration [44, 45], the role 
of Ca2+ homeostasis in migration was also studied. 2D 
migration experiments were carried in fibronectin layer and 
length (distance traveled) and speed were measured (Figure 
5D). Both factors were higher in 32d-p210 cells (Figure 
5D), which confirms the enhanced spontaneous migration of 
Bcr-Abl-expressing cells as previously described [44]. The 
pharmacological inhibition of SOCE induced an increase 
of spontaneous cell migration in 32-p210 cells (length and 
speed). SOCE has been reported to regulate migration in 
several previous studies, but the inhibition of SOCE usually 
reduced motility of cancer cells (for review: [27, 46]). 
Nevertheless several recent studies described that decrease 
of cytosolic Ca2+ could lead to an increase of cell migration 
[47, 48]. Similarly, the inhibition of Ca2+ channels in our 
model of hematopoietic progenitors induced an increase 
of cell motility. This suggests that the reduction of SOCE 
in Bcr-Abl-expressing cells is participating (together with 
RhoA activation for instance) to the enhanced spontaneous 
migration of these progenitors. 
Imatinib and calcium influxes
Imatinib is the first line TKI used to treat CML 
patients. We used imatinib to study the link between 
Ca2+ influx and kinase activity of Bcr-Abl. In thrombin-
stimulated 32-p210 cells, imatinib induced only a small 
decrease of the half-time of response compared to non-
treated cells (Figure 6A and 6B). In contrast, imatinib 
incubation strongly increased SOCE (maximum and 
slope) in 32-p210 cells to a level comparable with the one 
measured in 32dWT cells (Figure 6C and 6E). Moreover, 
TKI did not change the ER depletion (maximum and area) 
(Figure 6D) in 32d-p210 but restored the SOCE. These 
results suggest that Bcr-Abl inhibits SOCE through TK 
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activity directly or indirectly (Figure 6E). The inhibition 
of SOCs by YM-58483 reduced SOCE as expected and 
only a weak additional effect could be measured in the 
presence of imatinib suggesting that tyrosine kinase 
activity regulates directly SOCE. 
We next tried to find a link between the Bcr-Abl 
expression and the deregulation of Ca2+ homeostasis. 
PKC proteins could represent a good candidate because 
they have been previously described to be deregulated 
in Bcr-Abl-expressing cells [49] and PKC can modulate 
SOCE in various cells [48, 50]. Inhibition of PKC with 
Figure 4: SOC constituents in 32d cells. (A) Expression of TRPC1, Orai1 and STIM1 in 32dWT and 32d-p210 cells. Cell lysates were 
loaded in 8% SDS-PAGE gel and western blot analysis were performed using β-actin as a loading control. (B) Quantification of proteins 
expression from 13 independent experiments using GeneTools image analysis 4.3.5 Software. **P < 0.005. (C) Phosphorylation state of 
TRPC1/Orai1/ STIM1. Phosphorylated proteins were revealed by the PhosTag™ molecules, which are able to interact with phosphate. 
PhosTag™ were introduced to the separation SDS-PAGE gel and delayed phosphoprotein migration. Each phosphorylated form could 
be separated and visualized with specific antibodies in Western Blot. Dephosphorylated (DeP) form of proteins of interest was used as 
a negative control. Cells were lysate after incubation in 1.8 mM Ca2+ buffer (Ctr) or after ER depletion (0 mM Ca2+-15 µM CPA during 
7 minutes) (CPA).
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Figure 5: SOCE dependent cellular processes. (A) NFAT2 translocation in 32d-p210 cells. Immunostaining of actin (Phalloidin, 
green), nucleus (TOPRO, blue) and NFTA2 (red) were done in 1.8 mM Ca2+ buffer + DMSO (ctr) or in 1.8 mM Ca2+ buffer-15 µM CPA 
(CPA) for 30 minutes”. Images were obtained using confocal microscopy; bar = 10 µm. (B) Quantification of NFAT2 translocation from 
cytoplasm to nucleus by analyzing nucleus/cytoplasm ratio of NFAT2 means intensity in 32dWT (dark) and 32d-p210 (grey) cells. Cells 
were fixed after incubation in 1.8 mM Ca2+ buffer + DMSO (ctr) for 30 minutes or after stimulation with 0 mM Ca2+ buffer-15 µM CPA 
for 7 minutes prior to 1.8 mM Ca2+ buffer-15 µM CPA for 30 min (CPA). Alternatively, cell were stimulated with 1 U/ml thrombin for 
30 minutes. Cells were pre-treated with 1 µM CsA for 30 minutes (CPA+CsA), or treated with 40 µM SKF-96365 (CPA+SKF-96365) or 
10 µM YM-58483 (CPA+YM-58483) during incubation 1.8 mM Ca2+-15 µM. CPA for 30 minutes. Bar graphs represent mean rates of 
nucleus/cytoplasm ratio of NFAT2 means intensity ± SEM. ***P < 0.001. (C) Proliferation rate of 32dWT and 32d-p210 in normal medium 
with or without 10 µM YM-58483. Cells viability was estimated with trypan blue coloration at 24, 48 and 72 hours of incubation. (D) 
Cell migration was quantified by tracking analyzed using Imaris software. Total length and mean speed of each cell were measured in 
normal medium supplemented or not with 40 µM SKF-96365. Cell migration was recorded at 37° C for 30 minutes using the spinning disk 
confocal microscope (Olympus IX81-ZDC).
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Figure 6: Role of Bcr-Abl tyrosine kinase activity. (A) Thrombin-induced Ca2+ entry in imatinib pretreated 32d-p210 cells. Cells 
were plated on fibronectin-coated coverslips and treated (dotted line) or not (solid line) with 10 µM imatinib for 4 hours and next incubated 
in 1.8 mM Ca2+ buffer-1 U/ml thrombin. (B) Quantification of half-time of response of thrombin-induced Ca2+ entry in imatinib pretreated 
32d-p210 cells. Bar graphs represent mean rates of half-time of response ± SEM in 32dWT (dark), in non-treated 32d-p210 (grey) and 
treated 32d-p210 (white) cells. The control values are pooled from different experiments. ***P < 0.001. (C) SOCE in imatinib pretreated 
32d-p210 cells. 32d-p210 cells were treated (dotted line) or not (grey line) with 10 µM imatinib for 4 hours. ER depletion was trigged by 
15 μM CPA in 0 mM Ca2+ solution and SOCE were visualized with 1.8 mM Ca2+ buffer incubation. Same protocol was performed to 
32dWT cells (dark) as control. (D) Quantification of ER depletion in non-treated 32d-p210 (grey) and treated 32d-p210 (white) cells with 
the maximum of depletion (340/380 nm fluorescence ratio, left panel) and the amount of Ca2+ release (area under the curve, right panel) 
after normalization of the response. (E) SOCE quantification in 32d cells treated or not with imatinib and/or Ca2+ channels blockers. 
32d-p210 cells were treated or not with 10 µM imatinib for 4 hours and 10 µM YM-58483 were injected or not before ER depletion. 
The maximum (340/380 nm fluorescence ratio; left panel) and the speed of entries (initial slope; right panel) were measured. Bar graphs 
represent mean rates ± SEM. ***P < 0.001.
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the non-selective inhibitor Bisindolylmaleimide (BIM) 
induced a decrease of SOCE (slope and maximum) in 
32dWT cells but no significant effect could be measured 
in 32d-p210 cells (Figure 7A). Ca2+ entries in 32dWT 
cells seem to be dependent on PKC activity in contrast 
to Bcr-Abl-expressing cells. This suggests that the PKC-
dependent pathway activating SOCE in control cells is 
already inhibited by Bcr-Abl in leukemia cells. Moreover, 
thrombin-stimulated Ca2+ entry was also dependent on 
PKC activity in 32dWT cells. In these conditions, BIM 
treatment induced a strong decrease of half-time of 
response comparable to the one observed when measuring 
only SOCE (Figure 7B). No strong difference was 
observed in half-time of response in 32d-p210 cells after 
BIM treatment. This suggests that in 32dWT cells, PKC 
could principally enhance SOCE, and in turn the duration 
of intracellular Ca2+ signal in response to thrombin. 
DISCUSSION
In this study, we explored the deregulation of Ca2+ 
homeostasis, particularly SOCE, in hematopoietic cells 
expressing p210bcr-abl oncogene. We showed that in 32d-
p210 cells, thrombin-dependent and store-dependent Ca2+ 
entries were significantly reduced compared to control 
cells. Interestingly, the participation of constitutive Ca2+ 
Figure 7: Role of PKC in calcium influxes. (A) SOCE quantification with or without PKC inhibitor (BIM) in 32dWT (dark) and 32d-
p210 (grey) cells. Cells were incubated or not with a PKC inhibitor BIM (10 µM for 30 minutes before CPA treatment) in 1.8 mM Ca2+ buffer. 
SOCs activation protocol was performed and SOCE were measured by the maximum (340/380 nm fluorescence ratio; left panel) and the speed 
of entries (initial slope; right panel). (B) Thrombin-induced Ca2+ entry quantification with or without PKC inhibitor (BIM) in 32dWT (dark) 
and 32d-p210 (grey) cells (half-time of response in seconds). Cells were incubated or not in 1.8 mM Ca2+ -10 µM BIM for 30 minutes before 
CPA treatment, and 1.8 mM Ca2+-1 U/ml thrombin buffer was added. Bar graphs represent mean rates ± SEM. ***P < 0.001.
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entry to the regulation of Ca2+ homeostasis was negligible, 
in contrast to breast cancer cells [33]. In agreement with 
previous works [31, 51], ER Ca2+ store depletion was 
also reduced in 32d-p210 cells (Figure 3B). Thrombin-
induced entries were characterized by two phases: a first 
peak followed by a sustained phase. This work showed 
that, following thrombin-elicited ER Ca2+ release, SOCE 
participated to the second sustained phase in both cell 
lines. However, this second phase was significantly 
shorter in Bcr-Abl-expressing cells, which is partly 
due to a reduction of SOCE and may contribute to the 
alteration of downstream Ca2+-dependent signaling 
pathways. Particularly, it is well known that a sustained 
Ca2+ response supported by SOCE is more efficient in 
promoting NFAT activation and translocation, than a 
transient Ca2+ increase. Surprisingly the first phase of 
thrombin-induced response (peak), mainly due to Ca2+ 
release, was also slightly dependent on extracellular Ca2+ 
only in Bcr-Abl-expressing cells. This suggests that Ca2+ 
entry may also participate to the resulting peak value due 
to changes in Ca2+ entry pathways. 
To understand the mechanism of SOCE reduction 
in leukemia cells, we explored expression levels of SOC 
constituents in comparison to control cells. No difference in 
STIM1 expression could be evidenced, but Orai1 expression 
was enhanced in 32d-p210 cells while TRPC1 expression 
was diminished. The molecular interaction between STIM1 
and Orai1 is now well-documented [52]: Orai1 was initially 
described to operate as a tetramer channel [11] and recently 
demonstrated to function  as a hexamer [53]. Increase in 
Orai1 expression leads to a decrease in CRAC channel 
activity by reducing STIM1/Orai1 binding stoichiometry 
[34, 35]. In addition, after its activation, Orai1 is inactivated 
in a fast Ca2+-dependent manner. This rapid Ca2+-dependent 
inactivation is dependent on Orai1 expression level. 
Indeed, in our cell model, the increase of Orai1 expression 
combined with a stable STIM1 expression could explain 
the decrease of SOCE in 32d-p210 (Figures 2 and 3). Thus, 
Orai1 stoichiometry is crucial for its different modes of 
action. We also observed a decrease in TRPC1 expression 
level in 32d-p210 cells. In addition to Orai1 channel, STIM1 
can also directly activate TRPC1 [18, 54, 55]. Other works 
have reported that TRPC1 is involved in SOCE through its 
recruitment after STIM1-dependent Orai1 activation [21]. 
Since TRPC1 has been involved in SOCE in smooth [56] 
and skeletal [57, 58] muscles and in salivary gland [59], 
a decrease in TRPC1 level could also participate to the 
reduction of SOCE in Bcr-Abl-expressing progenitors. 
However, it is admitted that SOCE are mainly supported 
by STIM1-dependent Orai1 channels in hematopoietic cells 
such as lymphocytes [60].
Many studies deal with the link between SOCE 
and cancer. These studies propose that STIM1 and Orai1 
mutations or deregulation of expression and/or activation of 
SOC constituents induced global modification of Ca2+ entries 
leading to alteration of cancer homeostasis [23, 61, 62]. 
SOCE regulates the main cancer processes such as apoptosis, 
proliferation and migration/invasion in tumors from epithelial 
origin [27, 63, 64] through modification of Ca2+ dependent 
pathways such as NFAT, Calmoduline (CaM) and its kinase 
(CaMK), and/or nuclear factor-kappa B (NFκB) (for review: 
[27, 65, 66]). As observed in several other models, SOCE 
activation induced NFAT1 and 2 nuclear translocation in 
both 32d cell lines (Figure 5). This is in agreement with the 
literature that links SOCE and NFAT pathway and suggests 
that NFAT could be a cancer target in solid tumors and 
leukemia (for review: [67]). Interestingly, NFAT translocation 
was reduced in 32d-p210 cells compared to 32dWT cells, 
a result to correlate with SOCE inhibition in Bcr-Abl-
expressing cells. In addition, control conditions showed lower 
basal nuclear NFAT in 32d-p210 cells, suggesting that Bcr-
Abl expression deregulates intracellular processes of Ca2+ 
homeostasis and in turn Ca2+-dependent signaling pathways 
such as the calcineurin/NFAT cascade. In fact, these reduced 
Ca2+ influxes could inhibit NFAT pathway, a mechanism 
known to enhance myeloid differentiation characteristic of 
CML [68].
Interestingly, TRPC1 knockdown in endothelium 
progenitor cells induces SOCE decrease leading to a 
reduced proliferation and migration [69]. Here, TRPC1 
expression and SOCE were reduced in 32d-p210 cells 
while proliferation rate remained higher than in control 
cells (Figures 3 and 5C). Nevertheless, SOCE seems 
to play a role in proliferation because SOCE inhibition 
induced a reduction of proliferation in both cell lines. 
This finding suggests that while SOCE regulates 32d 
cell proliferation, Ca2+ independent pathways seem to 
be predominant in Bcr-Abl-dependent activation of 
enhanced cell proliferation. Bcr-Abl is known to control 
cell proliferation by tyrosine kinase dependent pathways 
such as Ras GTPase/ Mitogen-Activated Protein Kinase 
(MAPK), Phosphoinositide 3-kinase (PI3K)/ Protein 
kinase B (Akt) or Janus Kinase (JAK)/ Signal Transducers 
and Activators of Transcription (STAT) [70]. However, 
cell proliferation could be reduced in 32d-p210 cells by 
treatment with Ca2+ channel blockers, showing that the 
inhibition of SOCE can help to counteract the proliferative 
effects of Bcr-Abl. This is in agreement with unpublished 
data from our laboratory indicating that cell proliferation 
is regulated by SOCE and tyrosine kinase activity through 
two distinct signaling cascades. 
Migration and invasion are important for LSC 
development in CML, in part to evade hematopoietic niche 
control. Among other pathways, these mechanisms are 
also under the control of Ca2+ influx. Bcr-Abl expression 
increased the length and speed of migration compared to 
control as already published (Figure 5E) [44, 45]. SOCE 
has been involved in migration in normal and cancer cells 
by regulating for instance cell adhesion and cytoskeleton 
dynamics [27]. The Ca2+ signal could be local or global 
into cells and acts on Ca2+ dependent proteins such 
as myosin light chain kinase (MLCK), PI3K or focal 
Oncotarget26321www.oncotarget.com
adhesion kinase (FAK) [46]. Migration is a key process 
for the Bcr-Abl stem cells to leave the hematopoetic 
niche to reach blood circulation where they proceed to 
final differentiation [71, 72]. Migration stimulation could 
reduce the recurrence of the disease by inducing the exit 
of the oncogenic cells from the niche. In this work, we 
showed that SOCE inhibition enhanced migration in both 
cell lines. SOCE inhibition in Bcr-Abl-expressing cells, 
which is linked to enhance migration, is in contradiction 
with most studies on other cell types. However, a recent 
publication showed a correlation between SOCE levels 
and invasiveness of different melanoma cells [48]. In this 
model, SOCE decrease was the consequence of Orai1 
phosphorylation by PKC. 
PKC has previously been involved in SOCE 
regulation by Orai1 phosphorylation [38, 73] and was also 
shown to regulate cell motility [74]. We were unsuccessful 
to show any modifications in Orai1 phosphorylation level 
in normal or SOCs-activated conditions (Figure 4C). 
Nevertheless, inhibition of PKC reduced SOCE in 
32dWT cells, suggesting an enhancement of SOCE 
by the kinase in stimulated WT cells. The stimulating 
effect of PKC in 32dWT cells could be partly due to 
TRPC1, which confers PKC and PIP2 activation on native 
TRPC-dependent SOCE in vascular myocytes [75, 76]. 
Interestingly, PKC inhibition had not effect on SOCE 
in Bcr-Abl-expressing cells (Figure 7A), supporting the 
idea that the PKC-dependent pathway enhancing SOCE 
in WT progenitor is inhibited by expression of Bcr-Abl, 
which in turn leads to the decrease in NFAT activation. 
The inhibition of PKC pathway could participate together 
with changes in Orai1 stoichiometry and decrease in 
TRPC1 level to the diminution of SOCE activation in 
Bcr-Abl-expressing cells. PKC phosphorylation regulates 
various pathways important in cancer development like 
proliferation, differentiation, migration and invasion. 
Different isoforms are known to be involved in different 
functions associated with CML as maturation of stem cells 
or differentiation. Depending on the isoform, the effect of 
Bcr-Abl on PKC is either activator (PKC iota, beta and 
alpha) or inhibitor (PKC delta). PKC modulation can 
interfere with Bcr-Abl-mediated deregulated pathways 
such as JAK/STAT, ERK or NFkB (for review: [49]). In 
combination with TKI, PKC activators (Bryostatin) have 
been tested in CML treatment showing a reduction of 
cell growth and increase of apoptosis [77, 78]. PKC is a 
good candidate to regulate SOCE in Bcr-Abl expressing 
cells even if no direct phosphorylation of SOC has been 
detected. A study using PEITC (Phenethylisothiocyanate), 
a potential cancer chemo preventive drug targeting PKC, 
described a crosstalk between Bcr-Abl and PKC though 
Raf1 and ERK1/2 pathways [79]. They showed that 
PEITC increased the sensibility to imatinib and reduced 
PKC expression. The double inhibitions of PKC and Bcr-
Abl downregulated ERK4/2 and Raf1 pathways and these 
effects were not found in single inhibition. 
Many alternative strategies are now developed in 
clinical trials to eradicate malignant TKI resistant clones. 
Among others, inhibition of signaling pathways (JAK2, 
PI3K/Akt/mTOR, Wnt/βcatenin, etc.), immunological 
approaches (Interferon-α (IFNα), vaccination, etc.) or 
niche targeting (stromal cytokines, stroma adhesion, etc.) 
are proposed in CML to reach stem cells [80–83]. Among 
numerous studies exploring alternate therapeutic approaches 
in CML, few are interested in the role of Ca2+ in Bcr-Abl-
expressing cells. A clinical trial showed that a combination 
of NFAT inhibitor cyclosporine with dasatinib facilitated 
leukemia cells elimination and improved survival of Bcr-Abl 
acute lymphoblastic leukemia [84]. Nevertheless, the phase 
1b of this clinical trial concluded that this combined treatment 
may not be well tolerated [85]. Although, a recent proteomic 
analysis revealed that Ca2+ homeostasis actors could be good 
targets in TKI-resistant CML [86]. Altogether, currently 
available SOCE inhibitors as GSK-7975A, YM-58483 or 
SKF-96365 could be more interesting molecules although 
work is in progress to improve their specificity [87, 88]. 
In conclusion, we unveiled a deregulation of Ca2+ 
signaling in Bcr-Abl-expressing cells. Above others, Bcr-
Abl seems to tightly regulate SOCE using different strategies: 
first, by modifying the expression levels of Orai1 and 
TRPC1, but not of STIM1, leading to a modification of the 
stoichiometry of the complex between STIM1 and Orai1 and/
or TRPC1; second, through PKC pathway inhibition: in WT 
cells, SOCEs are clearly dependent on PKC activity while in 
Bcr-Abl expressing cells the dependency is lost. This suggests 
that Bcr-Abl already inhibits PKC activity or expression, 
which in turn regulates Ca2+ homeostasis. The reduction of 
SOCE activation by Bcr-Abl has various important effects, 
notably, the decrease of Ca2+ signal duration in response to 
agonist such as thrombin, and the lower activation of NFAT 
transcription factor, which needs to be dephosphorylated 
by the Ca2+-dependent phosphatase calcineurin and is 
maintained into the nucleus by long-lasting Ca2+ response. 
By decreasing SOCE activation, Bcr-Abl is thus able to 
reduce the activation of Ca2+-dependent signaling pathways 
such as the calcineurin/NFAT cascade. Future studies aiming 
at enhancing SOCEs in CML treatment in parallel with TKI 
should open new perspectives.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies against TRPC1 (SantaCruz), STIM1/GOK 
(BD Biosciences), NFAT1 and NFAT2 (Abcam) were mouse 
monoclonal. Antibodies against Orai1 (SantaCruz) and β-actin 
(Sigma-Aldrich) were rabbit polyclonal. Secondary horseradish 
peroxidase-conjugated (HRP)-conjugated goat anti-mouse IgG 
and goat anti-rabbit IgG were obtained from GE Healthcare 
(VWR International). Cyclopiazonic acid (CPA); N,N,N′,N′-
tetrakis(2-pyridylmethyl)ethilenediamine (TPEN); Thrombin; 
1{β-[3-(4-methoxyphenyl)propoxyl]-4-methoxyphenethyl}-
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1H-imidazole hydrochloride (SKF-96365); 4-methyl-4′-
[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-
5-carboxanilide (YM-58483); Cyclosporin A (CsA) and 
Bisindolylmaleimide (BIM) were all purchased from Sigma-
Aldrich. Fura-2-Acetoxymethyl ester (Fura-2 AM) was 
acquired from SantaCruz, GSK-7579A from Aobious, INC; 
whereas 1,3-bis [bis (pyridin-2-ylméthyl) amino] propan-
2-olato dizinc (II) complex (Phos-tag™ Acrylamide) was 
obtained from Wako Pure Chemical Industries Ltd. Imatinib 
mesylate was a gift from Dr E. Buchdunger (Novartis).
Cell culture
32d is an Interleukine- 3 (IL-3)-dependent myeloid 
progenitor cell line of murine origin. 32d-p210 cells 
were generated as previously described [89, 90]. All 
cells were maintained in standard RPMI 1640 medium 
(Lonza AG) containing 10% FBS (Foetal Bovine Serum) 
(Gibco BRL; Fisher Scientific) and 50 µg/ml gentamycin 
(Sigma-Aldrich). Wild-type 32d (32dWT) culture medium 
was supplemented with 0.05 ng/ml recombinant mouse 
IL-3 (Miltenyi Biotech). All cells were maintained in a 
humidified 37° C incubator with 5% CO2.
Cytosolic Ca2+ measurements
Cells were immobilized on fibronectin-coated 
coverslips for 4 hours and incubated in 1.8 mM Ca2+ buffer 
(130 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM 
MgCl2, 10 mM HEPES, and 5.6 mM glucose, pH 7.4, with 
NaOH) and loaded with 3 μM Fura 2-AM for 30 minutes 
at 37° C, 5% CO2. Next, cells were washed with 1.8 mM 
Ca2+ solution. Ca2+ influx were measured in response to 1 
U/ml thrombin in 1.8 mM Ca2+ buffer or after ER depletion 
induced by 15 µM CPA or 1 µM TPEN in Ca2+-free solution 
(130 mM NaCl, 5.4 mM KCl, 0.1 mM EGTA, 0.8 mM 
MgCl2, 10 mM HEPES, and 5.6 mM glucose, pH 7.4, with 
NaOH). Cells were treated or not with 10 µM imatinib for 
4 hours or 10 µM BIM for 30 minutes. Fura 2-loaded cells 
were excited alternatively at 340 and 380 nm with a CAIRN 
monochromator (Cairn Research Limited, Faversham, 
UK), and the fluorescence emissions of each cell were 
simultaneously monitored at 510 nm using a CCD camera 
(Photonic Science, Robertsbridge, UK) coupled to an 
Olympus IX70 inverted microscope (×40 water immersion 
fluorescence objective). The variation of fluorescence 
was recorded with the Imaging Workbench 4.0 (IW 4.0) 
software (IndecBioSystems, Mountain View, CA, USA). 
Intracellular Ca2+ measurements are shown as 340/380 nm 
ratios and analyzed with Origin 5.0 Software (Microcal 
Software, Northampton, MA, USA).
Cell lysis and western blotting
Proteins were extracted using RIPA buffer (50 mM 
Tris·HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 5 mM 
MgCl2, 0.05% NP-40, 1% sodium deoxycholate, 1% Triton 
X-100, 0.1% SDS supplemented with anti-phosphatase 
1X and anti-protease cocktail 1X (Sigma-Aldrich)). 
Cell extract was then sonicated and heated during 5 
minutes at 95° C. Protein extracts were dosed using 
BCA kit (Sigma-Aldrich). Samples were then subjected 
to SDS-PAGE and Western blot analysis as described 
previously [91, 92]. The blots were treated with primary 
antibody solutions overnight then for 1 hour with 
secondary HRP-conjugated antibody and developed with 
enhanced chemiluminescence kit (Merck Millipore). The 
apparent molecular weight was estimated according to the 
position of prestained protein markers (Kaleidoscope; Bio-
Rad). The density of β-actin served as an internal loading 
control and levels of protein expression were quantified by 
GeneTools image analysis 4.3.5 Software.
Phosphorylation assay
Cells were incubated in 1.8 mM Ca2+ buffer 
(control) or in Ca2+-free solution supplemented with 15 
µM CPA for 6 minutes at room temperature (RT) and then 
stimulated with 1.8 mM Ca2+ buffer for 1 minute before 
centrifugation. Proteins were extracted like described 
previously. 25 μM of acrylamide-pendant Phos-Tag™ 
ligand and 50 μM of MnCl2 were included in the separating 
gel before polymerization according to the protocol of 
Kinoshita and al., [39]. Dephosphorylated sample was 
obtained in NE buffer 1X (50 mM Hepes, 100 mM NaCl, 
2 mM DTT, 0.01% Brij 35, pH7.5 at 25° C) supplemented 
with 1 mM MnCl2 and 1U Protein Phosphatase Lambda 
(New England Biolabs) during 1 hour at 30° C.
Imaging of NFAT translocation
Cells were immobilized on fibronectin-coated 
coverslips and incubated in complete medium 
supplemented with 2 mM CaCl2 and 10 mM Hepes 
(Sigma-Aldrich). Cells were stimulated for 7 minutes at 
37° C with Ca2+-free solution + 15 µM CPA or 30 minutes 
with 1.8 mM Ca2+ buffer + 1 U/ml thrombin. After CPA 
stimulation, 1.8 mM Ca2+ buffer + 15 µM CPA with or 
without 40 µM SKF-96365 or 10 µM YM-58483 were 
added during 30 minutes. 1 µM CsA was added on cells 
30 minutes prior to CPA incubation. Cells were fixed in 
PBS (130 mM NaCl; 2.07 mM KCl; 1.5 mM Na2HPO4; 
8 mM KH2PO4, pH 7.4)/4% paraformaldehyde for 
30 minutes and permeabilized with PBS/0.3% Triton 
X-100 for 5 minutes. Primary antibodies were added 
overnight in PBS/1% BSA (dilution 1/50 for NFAT1 and 
1/100 for NFTA2) and then with fluorescent secondary 
antibodies (1/500) for 1 hour. 1 µg/ml TOPRO and 1 µg/
ml phalloidin (Sigma-Aldrich) were added for 20 minutes. 
Fluorescence was observed with confocal laser scanning 
microscopy using a Bio-Rad MRC 1024 ES equipped 
with an argon-krypton gas laser. Data were acquired using 
an inverted microscope (Olympus IX70) with ×60 oil 
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immersion objective (image processing was performed 
with Olympus Fluoview (FV10-ASW 2.0)). Quantification 
of nuclear translocation was assessed by calculating the 
nuclear/cytosolic fluorescence intensity mean ratio of 
NFAT by Image J Software. 
Cell proliferation assay
Cells were cultured at a concentration of 2 × 105 
cells/ml in complete medium and exposed to 10 µM YM-
58483. Cell proliferation was assessed by counting on 
Malassez chamber at 24, 48 and 72 hours using trypan 
blue solution (Sigma-Aldrich).
Cell cycle analysis assay
Cells were fixed in ice-cold ethanol (70% v/v) and 
stained with a solution of propidium iodide (PI) (5 μg/ml 
PI; 200 μg/ml RNase; 0.1% Triton X-100 in PBS) in 
the dark at RT for 1 hour 30 minutes. The DNA content 
was determined using a FACSVerse flow cytometer 
(BD Biosciences). Cell-cycle distribution was analysed 
using FlowJo 10.1 Software. Cells with DNA content 
between 2N and 4N were designated as being in the G1, 
S, or G2/M phase of the cell cycle. The number of cells 
in each compartment of the cell cycle was expressed as a 
percentage of the total number of counted cells (50.000 
events).
Migration assay
Cells were incubated on fibronectin coated 
coverslips and exposed to 40 μM SKF-96365. Cell 
migration was recorded during 30 minutes at 37° C with 
spinning disk confocal microscope (Olympus IX81-
ZDC). Length and straightness of the migrating cells were 
measured with Imaris Software.
Statistics
Experimental findings were expressed as 
mean ± standard deviation. Graphs were created using 
GraphPad Prism 5 Software. Statistical analysis was 
performed by Student’s t test. P < 0.05*, P < 0.01** and 
P < 0.001***.
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